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Left or r ight? Directions to stem cell engraftment
In this issue of JEM, Wu et al. (https ://doi .org /10 .1084 /jem .20171341) use genetic barcoding of macaque hematopoietic stem 
cells to demonstrate that, after transplantation, HSCs are very asymmetrically distributed and uncover a thymus-independent 
pathway for mature T cell production in the bone marrow.
Hematopoietic stem cells (HSCs) pro-
duce all blood cell lineages for the entire 
lifespan of an organism. Therapeutically, 
transplantation of HSCs is used to treat 
patients with a variety of hematological 
disorders or metabolic diseases. HSC 
transplantation (HSCT) is arguably the 
only stem cell therapy that is routinely 
performed, now in hundreds of thou-
sands of patients. Surprisingly, though, 
our understanding of the locational fate 
of transplanted HSCs is very limited. 
For instance, we do not know where 
HSCs land (or home) in the bone mar-
row, when and where HSC mobiliza-
tion takes place, nor whether there are 
lineage-specific production sites in the 
marrow.
To address some of these questions, 
in this issue, Wu et al. studied the fate of 
peripheral blood CD34+ hematopoietic 
stem and progenitor cells (HSPCs) and 
their progeny upon autologous trans-
plantation in rhesus macaques. Using a 
genetic barcoding strategy, analogously 
as has been done previously in murine 
(Gerrits et al., 2010; Naik et al., 2013) 
and human xenotransplantation studies 
(Cheung et al., 2013; Brugman et al., 
2015), the authors quantitatively tracked 
hundreds of HSPCs over time and space. 
At multiple time points after transplan-
tation, barcode composition, represent-
ing the quantitative output of individual 
HSCs, was measured in peripheral blood 
cells, lymph nodes, and two anatomically 
distinct bone marrow sites (the left and 
right iliac crest). These analyses revealed 
that the transplanted HSC clones were 
highly asymmetrically localized across 
different anatomical sites. Despite rapid 
normalization of blood counts and bone 
marrow cellularity, HSC equilibration 
between different marrow sites took 
months to sometimes years. Notably, 
HSC mobilization followed a tri-phasic 
pattern, characterized by HSC homing, 
followed by local blood cell production 
at the site of (potential) engraftment, and 
only later mobilization and equilibration 
in distant sites. In addition, by compar-
ing clonal patterns of more differentiated 
cells across different anatomical loca-
tions, the authors were able to delineate 
clonal hierarchies and preferred sites of 
production of certain cell types. For in-
stance, they demonstrate that the clonal 
origins of CD16+ and CD56+ NK cells 
are distinct and that CD16−CD56+ NK 
cells are preferentially produced in the 
bone marrow, whereas CD16+CD56− 
NK cell production preferentially takes 
place in extramedullary sites. Finally, the 
authors also identify the local, site-spe-
cific presence of CD3+ T cell popula-
tions in bone marrow, which are clonally 
related to their surrounding CD34+ 
HSCs, suggestive of their local, thy-
mus-independent production.
These results, in conjunction with 
previous studies, demonstrate the value 
of genetic barcoding to assess HSC dy-
namics, revealing intriguing and hith-
erto unappreciated spatial asymmetry 
of normal HSCs after transplantation 
(Verovskaya et al., 2014; Bystrykh and 
Belderbos, 2016). Simultaneously, these 
findings raise multiple questions.
For instance, the mechanisms 
guiding HSC migration to and from 
specific anatomical sites remain unclear. 
Understanding these mechanisms is of 
great interest, as this may yield new 
therapeutic opportunities to enhance/
accelerate HSC engraftment upon 
transplantation. The work by Wu et al. 
(2018) is consistent with a tri-phasic 
model of HSC engraftment and mo-
bilization upon HSCT (see figure, part 
A). First, transplanted HSCs home and 
engraft in different anatomical sites, 
which is characterized by marked asym-
metry. Although it is tempting to spec-
ulate that this early asymmetry reflects 
functional differences between HSCs 
and their niche, one should bear in 
mind that the observed clonal distribu-
tion patterns may also be explained by 
the single-cell nature of the barcoding 
technique. After all, a single HSC can 
only home and engraft to one anatom-
ical site. As HSC niches in the left and 
right iliac crest are presumably highly 
similar, the initial differences in clonal 
composition between these locations 
observed by Wu et al. (2018) are likely 
stochastic. Nonetheless, in other stud-
ies, many differences have been identi-
fied in the composition of HSC niches 
between more distant anatomical sites, 
which have been postulated to drive 
HSC diversity (Morrison and Scadden, 
2014). Accordingly, bidirectional com-
munication between HSCs and their 
niche may dictate HSC homing and/or 
fate upon (stochastic) engraftment in a 
certain site.
The second phase of engraftment 
is characterized by local HSC prolifer-
ation, resulting in simultaneous detec-
tion of CD34+ HSCs and their clonal 
progeny at the site of engraftment, but 
not at distant sites (see figure, part B). 
Although the clonal progeny of some 
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2HSCs can egress from their niche, the 
majority of HSC clones are still con-
fined to their site of initial engraftment, 
resulting in marked asymmetry at the 
bone marrow level. Importantly, in the 
paper by Wu et al. (2018), the ability of 
HSCs to contribute to blood formation 
early after transplantation seemed to be 
independent of their clone size in the 
bone marrow, suggesting that factors 
other than proliferation allow for their 
mobilization. In clinical transplantation 
protocols, the interval between HSCT 
and blood cell recovery is the major 
predictor of patient outcome. Accord-
ingly, insight into the mechanisms in-
ducing HSC mobilization to blood may 
identify novel targets to accelerate en-
graftment and improve the outcome of 
clinical HSCT recipients.
Finally, the third phase of HSC 
engraftment consists of gradual equili-
bration over the skeleton over a period 
of months to years (see figure, part C), 
ultimately resulting in HSC symmetry, 
in which the majority of (large) HSC 
clones are present in all locations. Of 
note, as Wu et al. (2018) restricted their 
analysis to major clones, the presence 
of residual asymmetry of minor clones 
cannot be excluded.
Regardless of the underlying 
mechanism, the findings by Wu et al. 
(2018) have important implications for 
fundamental studies on HSC biology, as 
well as for clinical HSCT procedures.
First, locational asymmetry may 
have a profound impact on the quan-
tification of HSC frequency. Currently, 
most experimental strategies to quantify 
HSC frequency rely on (xeno)-trans-
plantation of a population of hema-
topoietic stem/progenitor cells, either 
labeled or in limiting dilution (Bystrykh 
et al., 2012; Cheung et al., 2013). Subse-
quently, HSC frequency is calculated by 
dividing the number of retrieved clones 
by the administered cell dose. However, 
if measurements are performed in a 
single location, before HSCs have fully 
equilibrated, this may result in a large 
number of clones remaining undetected 
and an underestimation of true HSC 
frequency.
Second, locational asymmetry af-
fects our understanding of clonal hierar-
chy. In the study by Wu et al. (2018), the 
relative abundance of individual clones 
varied according to the location sam-
pled. Especially at early time points after 
transplantation, the majority of domi-
nant clones in the left iliac crest were 
minor in the right iliac crest, and vice 
versa. Accordingly, clonal abundance in 
a single location may not necessarily re-
flect dominance in the total body (i.e., 
if all sites were analyzed). In fact, clonal 
dominance in the peripheral blood (re-
ferred to as clonal hematopoiesis of in-
determinate potential), which has now 
been well established to occur during 
ageing in humans (Steensma et al., 
2015), may not reflect clonal dominance 
at the bone marrow stem cell level. In 
addition, a decreasing size of a specific 
clone in one location may not reflect its 
decreased fitness compared with other 
clones, but may also indicate enhanced 
capacity to mobilize and engraft in other 
sites. Altogether, elaborate clone-track-
ing strategies, sampling multiple skele-
tal sites at multiple time points, will be 
needed to fully assess and discriminate 
HSC clonal complexity and dynamics.
Third, because of the lack of 
unique markers to identify HSCs and 
their clonal offspring in humans, their 
anatomical distribution in human recip-
ients is still unknown. Nonetheless, the 
study by Wu et al. (2018) implies that 
sampling of a single skeletal site early 
after transplantation may not be suffi-
cient to monitor engraftment and that 
clonal analyses in blood may be more 
representative. In the future, single-cell 
next generation sequencing technology 
may allow investigation of HSC dynam-
ics and locational distribution in human 
recipients. These studies will be essential 
to determine how interactions between 
the bone marrow niche and transplanted 
donor HSC influence HSC fate, how 
factors like donor source and condi-
tioning regimen impact HSC distribu-
tion, and how these can be exploited to 
enhance bone marrow reconstitution 
upon HSCT.
Finally, similar to the spatial asym-
metry of normal HSCs observed in the 
current study, spatial diversity has also 
been shown to occur in malignancy. In 
solid tumors, the spectrum of genetic 
mutations differs between different lo-
cations within an individual tumor 
(Eirew et al., 2015; Lan et al., 2017) and 
between the primary tumor and meta-
static sites (Turajlic and Swanton, 2016). 
A tri-phasic model of HSC engraftment. The top circle graphs demonstrate HSC distribution 
across different anatomical locations in several phases after transplantation. The bottom 
bar graphs show the resulting clonal complexity. (A) Early after transplantation, HSC 
distribution is characterized by marked asymmetry intrinsic to single-cell engraftment. 
(B) Subsequently, HSC proliferation produces clonal offspring, which are initially largely 
confined to their initial site of production. Only few clones (for as yet unknown reasons) 
have the capacity to mobilize, which is clone-size independent. (C) Only months to years 
after transplant, HSC composition equilibrates across different sites. In the example 
given, at each time point, several clones is found in blood that is not present in any of the 












In recent xenograft studies, a similar pro-
cess is suggested to apply to hematologic 
malignancies as well (Belderbos et al., 
2017; Elder et al., 2017). This is of vital 
importance, as it suggests that clones may 
“hide” in certain skeletal locations and 
that sampling of a single bone marrow 
site, as is now common clinical practice, 
may be insufficient to capture full tumor 
heterogeneity. Moreover, as the local 
microenvironment can influence tumor 
cell properties, locational asymmetry 
may contribute to tumor heterogeneity 
and drive therapeutic resistance and dis-
ease relapse.
In sum, dissecting the degree of 
spatial asymmetry of normal HSCs and 
of their malignant counterparts will be 
of significant interest for our under-
standing of normal hematopoiesis and 
leukemia. In particular, it will be key to 
determine whether anatomical localiza-
tion impacts on essential cell properties 
like proliferation, differentiation and 
sensitivity to therapeutic agents.
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